Table 4.
Clinical data of the eight women with pregnancies until their responses to the written questionnaire (median age at pregnancy 29 years)
| Pregnancy | Cancer, anticancer therapy | Cryo-preservation | GnRH agonists | Age at diagnosis (age at pregnancy) in years | Interval to pregnancy (years since diagnosis) | Comments | |
|---|---|---|---|---|---|---|---|
| 1 BK | Birth of a healthy child | Breast cancer (Triple negative pT2, pN1a [1/11 LK], L0, V0, G3) 4 × EC, Docetaxel | + | − | 23 (27) | 4 | No utilisation of tissue |
| 2 SC | Birth of two healthy children | Hodgkin lymphoma Stage IIIB, 8 × BEACOPP esc | + | + | 21 (28) | 7 | No utilisation of tissue |
| 3 BA | Birth of a healthy child | NHL CHOP, Rituximab | − | + | 28 (36) | 8 | – |
| 4 BM | Birth of a healthy child | Hodgkin lymphoma stage IB, 2 ABVD | − | + | 24 (30) | 6 | – |
| 5 PL | Pregnant | Hodgkin lymphoma stage 2A, 4 × ABVD | + | + | 20 (27) | 7 | No utilisation of tissue |
| 6 BB | Pregnant | Osteosarcoma, 7 × VIDE | + | + | 21 (27) | 6 | No utilisation of tissue |
| 7 FK | Pregnant | Hodgkin lymphoma stage III, 6 × BEACOPP | + | − | 29 (32) | 3 | No utilisation of tissue |
| 8 GU | Pregnant | Breast cancer (pT1c, pN0, pM0, V0, L0, G3, E and P positive, Her2neu neg., 4 × EC, Taxotere) | + | + | 27 (34) | 7 | No utilisation of tissue |
EC Epirubicin Cyclophosphamid; BEACOPP esc Bleomycin, Etoposid, Adriamycin, Cyclophosphamide, Oncovin, Procarbazine, Prednisone in dose-escalation; NHL nonHodgkin-Lymphoma; CHOP Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone; ABVD Adriamycine, Bleomycin, Vinblastine, Dacarbazine; VIDE Vincristine, Ifosfamide, Doxorubicin, Etoposide